Company intelligence / Profile preview

NeurogesX

San Mateo, California, USAastellas.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeurogesX developed Qutenza, a capsaicin-based treatment for neuropathic pain, which was approved in the U.S. and EU. The company also had NGX-1998 in clinical trials but is no longer active.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small moleculestopical formulations
Industry: Biotech

Drug pipeline

2 assets

capsaicin

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

Astellas Pharma Europe Ltd. for Qutenza marketing in Europe

Beyond the preview

Go deeper on NeurogesX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeurogesX.

Explore the full profile